Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia (APL) is a subtype of acute myeloid leukemia characterized by the accumulation of immature granulocytic cells called promyelocytes in the bone marrow and blood.
It is often associated with a specific chromosomal translocation that fuses the PML and RARA genes, resulting in a fusion protein that disrupts normal cell differentiation.
APL is a medical emergency due to its high risk of bleeding and thrombosis.
Early recognition and prompt initiation of treatment, typically with all-trans retinoic acid and arsenic trioxide, are crucial for improving patient outcomes.
Researchers can leverage PubCompare.ai, an innovative AI-driven platform, to optimize their APL research by locating relevant protocols from literature, preprints, and patents, while utilizing AI-comparisons to identify the best approaches and products.
This tool can enhance reproducibility and accuracy in APL research, supporting advancements in the understanding and treatment of this potentially life-threatening condition.

Most cited protocols related to «Acute Promyelocytic Leukemia»

1
Randomized Trial of Bortezomib for Pediatric AML
The AAML1031 study was an open-label multi-center randomized trial including patients aged 0 to 29.5 years with previously untreated primary AML. Exclusion criteria were: prior chemotherapy, acute promyelocytic leukemia [t(15;17)], juvenile myelomonocytic leukemia, bone marrow failure syndromes, or secondary AML. The National Cancer Institute’s central institutional review board (IRB) and IRB at each enrolling center approved the study; patients and families provided informed consent or assent as appropriate. The trial was conducted in accordance with the Declaration of Helsinki. The trial was registered at clinicaltrials.gov identifier: NCT01371981.
Patients were randomly assigned at enrollment to either standard AML treatment or standard treatment with bortezomib. Randomization was conducted in blocks of four. Bortezomib was administered at a dose of 1.3 mg/m2 once on days 1, 4, and 8 of each chemotherapy course.
Patients with high allelic ratio FLT3 ITD were offered enrollment on a phase I sorafenib treatment arm if that arm was open. Patients with HAR FLT3 ITD who declined enrollment in the sorafenib arm, or who enrolled while the arm was suspended, continued to receive treatment according to their initial randomization. These patients were included in safety analyses but were excluded from all efficacy analyses.
Patients were classified as low- or high-risk after Induction I. Low-risk patients received four courses of chemotherapy and high-risk patients received three courses of chemotherapy followed by allogeneic SCT. High-risk patients without an appropriate donor received four courses of chemotherapy.
The primary end point was EFS from study entry. EFS was defined as the time from study entry until death, refractory disease, or relapse of any type, whichever occurred first. The secondary end points were OS, remission rates, relapse risk, post induction disease-free survival (DFS), and treatment-related mortality (TRM). OS was defined as time from study entry until death. Relapse risk was defined as the time from the end of Induction II for patients in complete remission (CR) to relapse, where deaths without a relapse were considered competing events. DFS was defined as the time from end of Induction II for patients in CR until relapse or death. Refractory disease was defined as the persistence of central nervous system (CNS) disease after Induction I, or the presence of morphologic bone marrow blasts ≥5% or any extramedullary disease at the end of Induction II. Patients with refractory disease were removed from protocol therapy. TRM was defined as the time from either study entry, or from end of Induction II for patients in CR, to deaths without a relapse, with relapses considered as competing events. Patients without an event were censored at their date of last known contact. However, for TRM analyses, patients were censored 30 days post end of therapy or 200 days post SCT.
Aplenc R., Meshinchi S., Sung L., Alonzo T., Choi J., Fisher B., Gerbing R., Hirsch B., Horton T., Kahwash S., Levine J., Loken M., Brodersen L., Pollard J., Raimondi S., Kolb E.A, & Gamis A. (2020). Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group. Haematologica, 105(7), 1879-1886.
Publication 2020
Acute Promyelocytic Leukemia Alleles Bone Marrow Bone Marrow Failure Disorders Bortezomib Central Nervous System Diseases Donors Ethics Committees, Research FLT3 protein, human Juvenile Myelomonocytic Leukemia Patients Pharmacotherapy Relapse Safety Sorafenib Therapeutics
2
Pediatric AML Treatment Protocol

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Acute Promyelocytic Leukemia Child Cytogenetic Analysis Diagnosis Down Syndrome Ethics Committees, Research FLT3 protein, human Fluorescent in Situ Hybridization Gene Rearrangement Legal Guardians Leukemia Parent Patients Point Mutation Reverse Transcriptase Polymerase Chain Reaction RUNX1 protein, human Therapeutics
3
Newly Diagnosed AML with FLT3 Mutations
Patients 18 to 59 years of age who had newly diagnosed AML and had not previously received antineoplastic therapy (except for limited urgent treatment for the current disease) were screened for FLT3 mutations. The patients provided written informed consent that allowed preregistration, and then a diagnostic bone marrow sample was obtained and submitted to one of nine academic laboratories for testing for FLT3 mutations.
Patients were registered in the trial if they had a FLT3 mutation and met the following other eligibility criteria: a diagnosis of AML (excluding acute promyelocytic leukemia) that was not therapy-related, a bilirubin level of less than 2.5 times the upper limit of the normal range, and the absence of other major coexisting illnesses. Hydroxyurea therapy was allowed for 5 days before the start of the trial therapy.
Stone R.M., Mandrekar S.J., Sanford B.L., Laumann K., Geyer S., Bloomfield C.D., Thiede C., Prior T.W., Döhner K., Marcucci G., Lo-Coco F., Klisovic R.B., Wei A., Sierra J., Sanz M.A., Brandwein J.M., de Witte T., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Krauter J., Schlenk R.F., Ganser A., Serve H., Ehninger G., Amadori S., Larson R.A, & Döhner H. (2017). Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England journal of medicine, 377(5), 454-464.
Publication 2017
Acute Promyelocytic Leukemia Antineoplastic Agents Bilirubin Bone Marrow Diagnosis Eligibility Determination FLT3 protein, human Hydroxyurea Mutation Patients Therapeutics
4
Intensive Chemotherapy for Newly Diagnosed AML
Between January 2000 and December 2014, a total of 976 patients with a newly diagnosed AML were consecutively treated with intensive chemotherapy at Toulouse University Hospital. The leukemia unit of the Toulouse University Hospital is the only certified center for the treatment of AML in the Midi-Pyrénées region (Southwest of France), which contains 3 million inhabitants. Patients are referred by personal physicians or primary care centers and are firstly seen by leukemia specialists either as outpatients for rapid diagnosis and work-up or directly as in patients if urgent medical interventions are needed. Patients from the Midi-Pyrénées area are recorded each week in the leukemia unit according to guidelines from the Oncomip network (http://www.oncomip.org) after informed consent. Patients were included in this study if they received at least one dose of intensive chemotherapy regimen. Patients with acute promyelocytic leukemia were not considered. The cytogenetic classification was in accordance with the Medical Research Council (MRC) classification9 (link). Molecular analyses were performed at diagnosis or retrospectively from samples stored in the tumor bank of the U1037 Inserm department (no. DC-2008-307-CPTP1 HIMIP)10 (link). Data were collected from the patients’ files and certified by the Data Management Committee of the anonymized AML database of Toulouse University Hospital and registered at the Commission Nationale de l’Informatique et des Libertés (CNIL) under access No. 1778920. In accordance with the Declaration of Helsinki, the study was reviewed and approved by the research ethics committee at Toulouse University Hospital.
Bertoli S., Tavitian S., Huynh A., Borel C., Guenounou S., Luquet I., Delabesse E., Sarry A., Laurent G., Attal M., Huguet F., Bérard E, & Récher C. (2017). Improved outcome for AML patients over the years 2000–2014. Blood Cancer Journal, 7(12), 635.
Publication 2017
Acute Promyelocytic Leukemia Diagnosis Ethics Committees, Research Leukemia Neoplasms Outpatients Patients Pharmacotherapy Physicians Primary Health Care Rapid Diagnostic Tests Specialists Treatment Protocols Vision
5
Neutralization Assays for Staphylococcal Toxins
Hla TNAs were performed as previously described (82 (link)). In brief, 4% rabbit red blood cells (RRBCs) were co-cultured with wild-type Hla ± serially diluted serum samples. Cells were centrifuged after 30 min and absorbance determined at OD416nm. PVL and LukAB TNAs were performed with human promyelocytic leukemia (HL-60) cells as previously described (25 (link)). In brief, differentiated HL-60 cells were incubated with either PVL or LukAB ± serially diluted serum samples for 3 h, and CellTiter Glo was added to the culture to measure cell viability. SAg TNAs were performed with PBMCS from healthy volunteers. Cells were co-cultured with SEA, SEB, or TSST-1 in the presence or absence of serially diluted serum samples for 48 h, supernatants were collected, and IFNγ was measured in the supernatants as a readout of superantigenicity as we previously described (26 (link)). Data were analyzed using a 4-parameter (4PL) curve fit in XLFit (Microsoft). Toxin neutralizing activity was defined as the effective dilution of sera at the point of the 4PL curve at which 50% of toxin activity was neutralized (ND50).
Karauzum H., Venkatasubramaniam A., Adhikari R.P., Kort T., Holtsberg F.W., Mukherjee I., Mednikov M., Ortines R., Nguyen N.T., Doan T.M., Diep B.A., Lee J.C, & Aman M.J. (2021). IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus. Frontiers in Immunology, 12, 624310.
Publication 2021
Acute Promyelocytic Leukemia Cells Cell Survival Erythrocytes Healthy Volunteers HL-60 Cells HLA Typing Homo sapiens Interferon Type II Rabbits Serum Superantigens Technique, Dilution Toxic Actions toxic shock syndrome toxin-1 Toxins, Biological

Most recents protocols related to «Acute Promyelocytic Leukemia»

1
Apoptosis Regulation in Leukemia Cells
Human promyelocytic leukemia cells (HL-60) and acute lymphatic leukemia cells (CCRF-CEM) were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences. DAC (A119533) was purchased from Aladdin (China). Lipofectamine® 2000 (11668-027) was purchased from Invitrogen (China). Opti-MEM (M5650) was purchased from Sigma (USA). The dual luciferase reporter gene assay kit (RG027) was purchased from Beyotime (China). The cell counting kit 8 (CCK8) (C1706) was purchased from Bioswamp (China). The SYBR FAST qPCR Master Mix (KM4101) was purchased from KAPA Biosystems (USA). The oligo DT18/miR-135a-5p RT Primer (3806), recombinant RNase inhibitor (2313A), and PrimeScript II RTase (2690A) were purchased from TAKARA (Japan). BCA protein concentration assay kit (PC0020) was purchased from Solarbio (China), DAB (DA1010) was purchased from Solarbio (China), and all antibodies (anti-Bad PAB32756; anti-Bcl-2 PAB30599; anti-cleaved-caspase-3 MAB37300; anti-GAPDH PAB36269; goat anti-rabbit IgG SAB43714) were purchased from Bioswamp (China).
Du F., Jin T, & Wang L. (2023). Mechanism of Action of Decitabine in the Treatment of Acute Myeloid Leukemia by Regulating LINC00599. Analytical Cellular Pathology (Amsterdam), 2023, 2951519.
Publication 2023
Acute Promyelocytic Leukemia anti-IgG Antibodies BCL2 protein, human Biological Assay Caspase 3 Cells Chinese Endoribonucleases GAPDH protein, human Genes, Reporter Goat Homo sapiens lipofectamine 2000 Luciferases Lymphoid Leukemia Oligonucleotide Primers Oligonucleotides Proteins Rabbits
2
Differentiation of HL-60 Cells into Neutrophil-like Cells
The human promyelocytic leukemia cell line HL-60 (ATCC CCL-240) was obtained from the American Type Culture Collection (ATCC). HL-60 cells were maintained in Iscove’s modified Dulbecco’s medium (IMDM; Gibco) supplemented with 20% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 1 mg/mL streptomycin and cultured in an incubator at 37°C with 5% CO2. Cells were routinely counted to maintain a density of between 105 and 106 cells/mL. HL-60 cells at a density of 106 cells/mL were differentiated into neutrophil-like cells using growth medium supplemented with 1.25% dimethyl sulfoxide (DMSO) and incubated for a period of 5 to 7 days. Prior to use in the assay, the cells were washed in IMDM, and viable cells were counted based on trypan blue exclusion using a hemocytometer. HL-60 cells were then suspended in IMDM plus 1% BSA at a concentration of 2 × 105 cells/mL for use in the opsonophagocytic killing assay (OPA).
Thompson C.D., Bradshaw J.L., Miller W.S., Vidal A.G., Vidal J.E., Rosch J.W., McDaniel L.S, & Keller L.E. (2023). Oligopeptide Transporters of Nonencapsulated Streptococcus pneumoniae Regulate CbpAC and PspA Expression and Reduce Complement-Mediated Clearance. mBio, 14(1), e03325-22.
Publication 2023
Acute Promyelocytic Leukemia Biological Assay Cell Lines Cells Culture Media Fetal Bovine Serum HL-60 Cells Homo sapiens Neutrophil Penicillins Streptomycin Sulfoxide, Dimethyl Trypan Blue
3
Alloreactive NK Cells for Adult Leukemia
The NK-AML multicenter clinical trial (NCT03955848) is based on the infusion of alloreactive NK cells as a consolidation strategy for adult leukemia patients. AML patients with high or intermediate risk de-novo or secondary disease, with age greater than 18 years, not eligible for HSCT due to medical contraindications or lack of donor, are eligible. AML of M3 FAB subtype are excluded from the study. The patients’ eligibility criteria require the presence of a haploidentical donor with alloreactive NK cells, and adequate renal, pulmonary and hepatic function. NK cell separation was performed using the CliniMACS system (Miltenyi Biotec) on total peripheral blood mononuclear cells obtained by leukapheresis from the selected donors (31 (link), 32 (link)). After immunosuppressive chemotherapy, including fludarabine and cyclophosphamide as previously described (31 (link)), patients were infused intravenously with a single dose of cryopreserved NK cells (day 0) followed by subcutaneous administration of IL-2 (10 x 106 IU/day, 3 times weekly; Novartis) for 2 weeks (6 doses total).
The MRD-NK clinical trial is based on the infusion of haploidentical KIR-L mismatched NK cells in adult AML patients, who are eligible for HSCT and achieved MRD-positive CR after conventional chemotherapy. Patients with active infections and/or abnormal renal, cardiac, pulmonary, and hepatic function and/or poor performance status are excluded. Immunosuppressive chemotherapy and IL-2 administration in this trial were superimposable to NK-AML.
Meazza R., Ruggeri L., Guolo F., Minetto P., Canevali P., Loiacono F., Ciardelli S., Bo A., Luchetti S., Serio A., Zannoni L., Retière C., Colomar-Carando N., Parisi S., Curti A., Lemoli R.M, & Pende D. (2023). Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire. Frontiers in Immunology, 14, 1111419.
Publication 2023
Acute Promyelocytic Leukemia Adult Cell Separation Cyclophosphamide Donors Eligibility Determination fludarabine Heart Immunosuppressive Agents Infection Kidney Leukapheresis Leukemia Lung Natural Killer Cells Patients PBMC Peripheral Blood Mononuclear Cells Pharmacotherapy Tissue Donors
4
Characterization of AML Samples
This cohort study included 171 samples; 73 BM and 98 PB samples from AML patients, 97 males (56.7%) and 74 females (43.3%) with a mean age of 38.5 years (SD 12.5) ranging from 18 to 63 years. All of these patients were presented to the inpatient clinic at the National Cancer Institute (NCI), Cairo University (CU), diagnosed between July 2012 to December 2017. Patients underwent routine laboratory investigations and imaging diagnoses and were classified according to the standard morphological and immunophenotyping (IPT) criteria. All samples were collected before treatment; patients were treated intensively with the standard protocol. Patients with acute promyelocytic leukemia (APL) were given All-trans retinoic acid (ATRA). Other FAB subtypes were given the 3 + 7 treatment protocol. Response to induction therapy was assessed between days 14 and 28 after induction therapy and none of them received hypomethylating therapy. Written informed consents were obtained from the patients or their legal guardians, and this study was approved by the ethical committee of NCI, CU, Egypt, and was in accordance with the 2011 Declaration of Helsinki (IRP Approval No. 201902012.4). The age and sex-matched group consists of 15 PB samples from healthy donors from the same hospital, and eight BM samples from volunteers for BM transplantation were selected as a control group.
Assem M., El-Araby R.E., Al-Karmalawy A.A., Nabil R., Kamal M.A., Belal A., Ghamry H.I., Abourehab M.A., Ghoneim M.M., Alshahrani M.Y, & El Leithy A.A. (2023). Promoter methylation might shift the balance of Galectin-3 & 12 expression in de novo adult acute myeloid leukemia patients. Frontiers in Genetics, 14, 1122864.
Publication 2023
Acute Promyelocytic Leukemia Diagnosis Donors Females Inpatient Legal Guardians Males Neoadjuvant Therapy Patients Therapeutics Transplantation Treatment Protocols Tretinoin Voluntary Workers
5
Synthesis and Characterization of Pyrazolyl-Thiazole Ligands
The human histiocytic lymphoma (U-937), human promyelocytic leukemia (HL- 60), and human epithelial cervix adenocarcinoma (HeLa) cell lines were purchased from the European Collection of Authenticated Cell Cultures (ECACC; Dorset, UK). All chemical reagents were acquired from commercial sources. The synthesis of the ligands 2-(1-pyrazolyl)-2-thiazoline (PzTn), 2-(3,5-dimethyl-1-pyrazolyl)-2-thiazoline (DMPzTn), 2-(3,5-diphenyl-1-pyrazolyl)-2-thiazoline (DPhPzTn), 2-(1-pyrazolyl)-1,3-thiazine (PzTz), 2-(3,5-dimethyl-1-pyrazolyl)-1,3-thiazine (DMPzTz) and 2-(3,5-diphenyl-1-pyrazolyl)-1,3-thiazine (DPhPzTz) was carried out as reported elsewhere [16 (link),17 (link),18 (link)].
The elemental analysis was performed with a microanalyzer (Leco CHNS-932). IR spectra were recorded on a Perkin-Elmer 100 FTIR spectrophotometer from KBr pellets in the 4000–400 cm−1 range. To obtain 1H NMR spectra, it was used a Bruker 48 instrument at 300 MHz for PdPzTn and PdPzTz, an AV300 instrument at 300 MHz for PdDMPzTn, and a Bruker Avance III 500 instrument at 500 MHz for PdDPhPzTn and PdDPhPzTz, in DMF-d7 or DMSO-d6 according to the complex solubility. 1H NMR data could not be obtained for PdDMPzTz due to its low solubility. 1H NMR signals were referenced to residual proton resonances in deuterated solvents.
Fernández-Delgado E., Estirado S., Rodríguez A.B., Luna-Giles F., Viñuelas-Zahínos E., Espino J, & Pariente J.A. (2023). Cytotoxic Effects of New Palladium(II) Complexes with Thiazine or Thiazoline Derivative Ligands in Tumor Cell Lines. Pharmaceutics, 15(2), 696.
Publication 2023
1H NMR A 300 Acute Promyelocytic Leukemia Adenocarcinoma Anabolism Cell Culture Techniques Cervix Uteri diphenyl Epithelial Cells Europeans Homo sapiens Infrared Spectrophotometry Ligands Pellets, Drug Protons Reticulosarcoma Solvents Spectroscopy, Fourier Transform Infrared Sulfoxide, Dimethyl Thiazines Vibration

Top products related to «Acute Promyelocytic Leukemia»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Hl 60 by American Type Culture Collection
Sourced in United States, Germany, United Kingdom, China, Australia
The HL-60 is a human promyelocytic leukemia cell line. It is a well-established in vitro model system for studying cellular differentiation and hematopoiesis.
3
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
4
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
5
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
6
Rpmi 1640 by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
7
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
8
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
9
Rpmi 1640 medium by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, Italy, China, France, Sao Tome and Principe, Switzerland, Austria, Australia, Spain, Macao, Belgium, Canada, Hungary, Brazil, Sweden, Ireland, India, Poland, Israel, Mexico, Denmark, Hong Kong, Czechia, Argentina, Portugal, Holy See (Vatican City State)
RPMI-1640 is a widely used cell culture medium formulation, developed at Roswell Park Memorial Institute. It is a complete and balanced medium designed to support the growth and maintenance of a variety of cell types, including human and animal cell lines. The medium contains essential nutrients, vitamins, amino acids, and other components necessary for cell proliferation and survival in in vitro cell culture applications.
10
Hl 60 by Thermo Fisher Scientific
Sourced in United States, United Kingdom
The HL-60 is a cell line derived from human promyelocytic leukemia cells. It is commonly used in cell biology and immunological research as a model system for studying cellular differentiation and signaling pathways.

More about "Acute Promyelocytic Leukemia"

Acute Promyelocytic Leukemia (APL) is a subtype of Acute Myeloid Leukemia (AML) characterized by the accumulation of immature granulocytic cells called promyelocytes in the bone marrow and blood.
This condition is often associated with a specific chromosomal translocation that fuses the PML and RARA genes, resulting in a fusion protein that disrupts normal cell differentiation.
APL is considered a medical emergency due to its high risk of bleeding and thrombosis.
Early recognition and prompt initiation of treatment, typically with all-trans retinoic acid (ATRA) and arsenic trioxide, are crucial for improving patient outcomes.
Researchers can leverage PubCompare.ai, an innovative AI-driven platform, to optimize their APL research by locating relevant protocols from literature, preprints, and patents, while utilizing AI-comparisons to identify the best approaches and products.
This tool can enhance reproducibility and accuracy in APL research, supporting advancements in the understanding and treatment of this potentially life-threatening condition.
Researchers may also utilize cell lines like HL-60 and culture media such as RPMI 1640, supplemented with fetal bovine serum (FBS) and antibiotics like penicillin and streptomycin, to study APL in vitro.
These standardized experimental setups can provide valuable insights into the biology and potential therapies for this disease.
By leveraging the power of AI-driven platforms and established cell culture techniques, scientists can accelerate their progress in unraveling the complexities of Acute Promyelocytic Leukemia and developing more effective treatments for patients.